Orkambi® (lumacaftor/ivacaftor) – Expanded indication and New formulation approval
August 7, 2018 - Vertex announced the FDA approval of Orkambi (lumacaftor/ivacaftor), for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene.
Top